



SAFETY DATA SHEET

Revision date: 09-March-2021

Version: 0.0

Page 1 of 9

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Clindamycin Phosphate Topical Gel

Chemical Family: Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used as antibiotic agent

Details of the Supplier of the Safety Data Sheet

Encube Ethicals Pvt. Ltd.

C/1, Madkaim Industrial Estate, Madkaim,
Ponda, Goa - 403404, India
Emergency telephone number:

Encube Ethicals Pvt. Ltd.

803, B Wing, HDIL Kaledonia, Sahar Road,
Andheri (E), Mumbai – 400 069
Emergency telephone number:

Contact E-Mail:

Contact E-Mail:

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification

Skin Sensitization: Category 1

Label Elements

Signal Word: Warning

Hazard Statements: H317 - May cause an allergic skin reaction

Precautionary Statements:

P261 - Avoid breathing dust/fume/gas/mist/vapors/spray
P271 - Use only outdoors or in a well-ventilated area
P280 - Wear protective gloves/protective clothing/eye protection/face protection
P302+ P352 - IF ON SKIN: Wash with plenty of soap and water
P333 + P313 - If skin irritation or rash occurs: Get medical advice/attention
P321 - Specific treatment (see supplemental instructions on the administration of antidotes on this label)
P363 - Wash contaminated clothing before reuse

SAFETY DATA SHEET

Material Name: Clindamycin Phosphate Topical Gel
Revision date: 09-March-2021

Page 2 of 9
Version: 0.0



Other Hazards

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

Note:

This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Clindamycin Phosphate	24729-96-2	246-433-0	Acute Tox.4 (H302) Eye Irrit.2A (H319) Skin Irrit.3 (H316) Skin Sens.1 (H317)	1
Propylene glycol	57-55-6	200-338-0	Not Listed	*

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Allantoin	97-59-6	202-592-8	Not Listed	*
Carbomer	54182-57-9	Not Listed	Not Listed	*
Methylparaben	99-76-3	202-785-7	Not Listed	*
Polyethylene glycol 400	25322-68-3	Not Listed	Not Listed	*
Water, purified	7732-18-5	231-791-2	Not Listed	*

Additional Information:

* Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.
In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact:

Flush with water while holding eyelids open for at least 15 minutes. If irritation occurs or persists, get medical attention.

Skin Contact:

Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

SAFETY DATA SHEET

Material Name: Clindamycin Phosphate Topical Gel
Revision date: 09-March-2021

Page 3 of 9
Version: 0.0

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO₂, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: Emits toxic fumes of carbon monoxide, carbon dioxide, nitrogen oxides, sulfur oxides and other sulfur-containing compounds.

Fire / Explosion Hazards: Not applicable

Advice for Fire-Fighters

During all firefighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Cleanup operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Specific end use(s): Pharmaceutical drug product

SAFETY DATA SHEET

Material Name: Clindamycin Phosphate Topical Gel
Revision date: 09-March-2021

Page 4 of 9
Version: 0.0

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

Clindamycin Phosphate

Encube Ethicals Pvt Ltd OEL TWA-8 Hr: 100µg/m³

Polyethylene glycol 400

Austria OEL - MAKs 1000 mg/m³
Germany - TRGS 900 - TWAs 1000 mg/m³
Germany (DFG) - MAK 1000 mg/m³ average molecular weight 200-600
Slovakia OEL - TWA 1000 mg/m³
Slovenia OEL - TWA 1000 mg/m³
Switzerland OEL -TWAs 1000 mg/m³

Propylene glycol

Australia TWA 150 ppm
474 mg/m³
10 mg/m³
Ireland OEL - TWAs 150 ppm
470 mg/m³
10 mg/m³
Latvia OEL - TWA 7 mg/m³
Lithuania OEL - TWA 7 mg/m³

Exposure Controls

Engineering Controls:

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal Protective Equipment:

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.

Hands:

Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.)

Eyes:

Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.)

Skin:

Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.)

Respiratory protection:

Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.)

SAFETY DATA SHEET

Material Name: Clindamycin Phosphate Topical Gel
Revision date: 09-March-2021

Page 5 of 9
Version: 0.0

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Gel	Color:	Clear, colorless
Odor:	No data available.	Odor Threshold:	No data available.
Molecular Formula:	Mixture	Molecular Weight:	Mixture

Solvent Solubility: No data available
Water Solubility: No data available
pH: No data available.
Melting/Freezing Point (°C): No data available
Boiling Point (°C): No data available.
Partition Coefficient: (Method, pH, Endpoint, Value)

Clindamycin Phosphate

No data available

Polyethylene glycol 400

No data available

Propylene glycol

No data available

Allantoin

No data available

Methylparaben

No data available

Carbomer

No data available

Water, purified

No data available

Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s): No data available

Vapor Pressure (kPa): No data available

Vapor Density (g/ml): No data available

Relative Density: No data available

Viscosity: No data available

Flammability:

Autoignition Temperature (Solid) (°C): No data available

Flammability (Solids): No data available

Flash Point (Liquid) (°C): No data available

Upper Explosive Limits (Liquid) (% by Vol.): No data available

Lower Explosive Limits (Liquid) (% by Vol.): No data available

10. STABILITY AND REACTIVITY

Reactivity: No data available
Chemical Stability: Stable at normal conditions

Possibility of Hazardous Reactions

Oxidizing Properties: No data available

Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.

Incompatible Materials: As a precautionary measure, keep away from strong oxidizers

Hazardous Decomposition Products: No data available

SAFETY DATA SHEET

Material Name: Clindamycin Phosphate Topical Gel
Revision date: 09-March-2021

Page 6 of 9
Version: 0.0

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information:

The information included in this section describes the potential hazards of the individual ingredients.

Short Term:

Active ingredient may be harmful if swallowed. May cause eye irritation. May cause mild skin irritation (based on animal data).

Known Clinical Effects:

Individuals sensitive to this material or other materials in its chemical class may develop allergic reactions. Clinical use of this drug has caused sore throat, fever gastrointestinal disturbances, abnormal liver function tests, kidney dysfunction. Pseudomembranous colitis (manifested by watery diarrhea, urge to defecate, abdominal cramps, low-grade fever, bloody stools, and abdominal pain) may also occur.

Acute Toxicity: (Species, Route, End Point, Dose)

Clindamycin Phosphate

Rat	Oral	LD 50	1832 mg/kg
Rat	Para-periosteal	LD 50	321mg/kg
Rat	Intraperitoneal	LD 50	745mg/kg
Mouse	Oral	LD 50	2359mg/kg
Mouse	Intravenous	LD 50	820mg/kg

Propylene glycol

Rat	Oral	LD 50	22,000 mg/kg
Mouse	Oral	LD 50	24,900mg/kg
Rabbit	Dermal	LD 50	20,800mg/kg

Acute Toxicity Comments:

A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Clindamycin Phosphate

Eye Irritation	Rabbit	Moderate
Skin Irritation	Rabbit	Mild

Polyethylene glycol 400

Eye Irritation	Rabbit	Mild
Skin Irritation	Rabbit	Mild

Propylene glycol

Skin Irritation	Rabbit	Mild
Eye Irritation	Rabbit	Mild

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Clindamycin Phosphate

6 Month(s)	Rat	Oral 600 mg/kg/day	NOAEL	No effects at maximum dose
6 Month(s)	Dog	Oral 600 mg/kg/day	NOAEL	Gastrointestinal system

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Clindamycin Phosphate

SAFETY DATA SHEET

Material Name: Clindamycin Phosphate Topical Gel
Revision date: 09-March-2021

Page 7 of 9
Version: 0.0

11. TOXICOLOGICAL INFORMATION

Prenatal & Postnatal Development	Rat	Subcutaneous 250 mg/kg	NOAEL	Not teratogenic
Prenatal & Postnatal Development	Rat	Oral 300 mg/kg/day	NOAEL	Not Teratogenic
Prenatal & Postnatal Development	Mouse	Oral 600 mg/kg/day	NOAEL	Not Teratogenic
Prenatal & Postnatal Development	Rabbit	Subcutaneous 5 mg/kg/day	NOAEL	Not Teratogenic, Maternal Toxicity
Reproductive & Fertility	Rat	Oral 300 mg/kg/day	NOAEL	No effects at maximum dose

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Clindamycin Phosphate

Bacterial Mutagenicity (Ames)	<i>Salmonella</i>	Negative
<i>In Vitro</i> Micronucleus	Rat	Negative

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

12. ECOLOGICAL INFORMATION

Environmental Overview:	Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.
Toxicity:	No data available
Persistence and Degradability:	No data available
Bio-accumulative Potential:	No data available
Mobility in Soil:	No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

SAFETY DATA SHEET

Material Name: Clindamycin Phosphate Topical Gel
Revision date: 09-March-2021

Page 8 of 9
Version: 0.0

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Allantoin

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	202-592-8

Carbomer

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
EU EINECS/ELINCS List	Not Listed

Clindamycin Phosphate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
EU EINECS/ELINCS List	246-433-0

Methylparaben

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	202-785-7

Polyethylene glycol 400

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 2 Schedule 3
EU EINECS/ELINCS List	Not Listed

Water, purified

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	231-791-2

Propylene glycol

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed

SAFETY DATA SHEET

Material Name: Clindamycin Phosphate Topical Gel
Revision date: 09-March-2021

Page 9 of 9
Version: 0.0

15. REGULATORY INFORMATION

Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	200-338-0

16. OTHER INFORMATION

Text of CLP/GHS Classification abbreviations mentioned in Section 3

Acute toxicity, oral-Cat.4; H302 - Harmful if swallowed
Serious eye damage/eye irritation-Cat.2A; H319 - Causes serious eye irritation
Sensitization, skin-Cat.1; H317 - May cause an allergic skin reaction
Skin corrosion/irritation-Cat.3; H316 - Causes mild skin irritation

Data Sources: Encube Ethicals Pvt. Ltd. proprietary drug development information. Safety data sheets for individual ingredients.

Reasons for Revision: NA

Revision date: 09-March-2022

Prepared by: Encube Ethicals Pvt. Ltd., Health, and Safety Operations

Encube Ethicals Pvt. believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet